Remote hemodynamic guidance before and after left ventricular assist device implantation: Short-Term results from the HEMO-VAD pilot study

Jesse F. Veenis; Sumant P. Radhoe; Nicolas M. Van Mieghem; Olivier C. Manintveld; Kadir Caliskan; Ozcan Birim; Jos A. Bekkers; Eric Boersma; Mattie J. Lenzen; Felix Zijlstra; Jasper J. Brugts

doi:10.2217/fca-2020-0182

Remote hemodynamic guidance before and after left ventricular assist device implantation: Short-Term results from the HEMO-VAD pilot study

Jesse F. Veenis, Sumant P. Radhoe, Nicolas M. Van Mieghem, Olivier C. Manintveld, Kadir Caliskan, Ozcan Birim, Jos A. Bekkers, Eric Boersma, Mattie J. Lenzen, Felix Zijlstra, Jasper J. Brugts^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Abstract

Aim: We aimed to assess the safety and feasibility of using CardioMEMS monitoring in patients before and after left ventricular assist device (LVAD) surgery. Patients and methods: Ten patients accepted for elective LVAD surgery were included, received a CardioMEMS at baseline and were categorized based on mean pulmonary artery pressure (mPAP) ?25 mmHg (n = 4) or mPAP >25 mmHg [n = 6]) before LVAD surgery. Results: The combined end point of all-cause mortality, acute kidney injury and/or renal replacement therapy, and right ventricular failure occurred more often in patients with an mPAP >25 mmHg (83 vs 0%, p = 0.017). Conclusion: This pilot study demonstrates that combining CardioMEMS monitoring with LVAD therapy is safe and generates the hypothesis that patients with an mPAP >25 mmHg before LVAD surgery identify a very high-risk group for adverse clinical outcomes.

Original language	English
Pages (from-to)	885-898
Number of pages	14
Journal	Future Cardiology
Volume	17
Issue number	5
Early online date	7 Jan 2021
DOIs	https://doi.org/10.2217/fca-2020-0182
Publication status	Published - Aug 2021

Bibliographical note

Funding Information:
This work was supported by Abbott with an independent research grant, partially covering personnel costs. This study was investigator-initiated and was designed, conducted, interpreted and reported independently of the funder by the CRO/sponsor Erasmus University Medical Center. JJ Brugts has received speaker fees from Abbott. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Publisher Copyright:
© 2021

Access to Document

10.2217/fca-2020-0182Licence: Unspecified

Cite this

Veenis, J. F., Radhoe, S. P., Van Mieghem, N. M., Manintveld, O. C., Caliskan, K., Birim, O., Bekkers, J. A., Boersma, E., Lenzen, M. J., Zijlstra, F., & Brugts, J. J. (2021). Remote hemodynamic guidance before and after left ventricular assist device implantation: Short-Term results from the HEMO-VAD pilot study. Future Cardiology, 17(5), 885-898. https://doi.org/10.2217/fca-2020-0182

@article{1f30e326cf8d480db4b2f83629d6678d,

title = "Remote hemodynamic guidance before and after left ventricular assist device implantation: Short-Term results from the HEMO-VAD pilot study",

abstract = "Aim: We aimed to assess the safety and feasibility of using CardioMEMS monitoring in patients before and after left ventricular assist device (LVAD) surgery. Patients and methods: Ten patients accepted for elective LVAD surgery were included, received a CardioMEMS at baseline and were categorized based on mean pulmonary artery pressure (mPAP) ?25 mmHg (n = 4) or mPAP >25 mmHg [n = 6]) before LVAD surgery. Results: The combined end point of all-cause mortality, acute kidney injury and/or renal replacement therapy, and right ventricular failure occurred more often in patients with an mPAP >25 mmHg (83 vs 0%, p = 0.017). Conclusion: This pilot study demonstrates that combining CardioMEMS monitoring with LVAD therapy is safe and generates the hypothesis that patients with an mPAP >25 mmHg before LVAD surgery identify a very high-risk group for adverse clinical outcomes. ",

author = "Veenis, {Jesse F.} and Radhoe, {Sumant P.} and {Van Mieghem}, {Nicolas M.} and Manintveld, {Olivier C.} and Kadir Caliskan and Ozcan Birim and Bekkers, {Jos A.} and Eric Boersma and Lenzen, {Mattie J.} and Felix Zijlstra and Brugts, {Jasper J.}",

note = "Funding Information: This work was supported by Abbott with an independent research grant, partially covering personnel costs. This study was investigator-initiated and was designed, conducted, interpreted and reported independently of the funder by the CRO/sponsor Erasmus University Medical Center. JJ Brugts has received speaker fees from Abbott. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2021 ",

year = "2021",

month = aug,

doi = "10.2217/fca-2020-0182",

language = "English",

volume = "17",

pages = "885--898",

journal = "Future Cardiology",

issn = "1479-6678",

publisher = "Future Medicine Ltd.",

number = "5",

}

Veenis, JF , Radhoe, SP , Van Mieghem, NM , Manintveld, OC , Caliskan, K , Birim, O , Bekkers, JA , Boersma, E , Lenzen, MJ , Zijlstra, F & Brugts, JJ 2021, 'Remote hemodynamic guidance before and after left ventricular assist device implantation: Short-Term results from the HEMO-VAD pilot study', Future Cardiology, vol. 17, no. 5, pp. 885-898. https://doi.org/10.2217/fca-2020-0182

TY - JOUR

T1 - Remote hemodynamic guidance before and after left ventricular assist device implantation

T2 - Short-Term results from the HEMO-VAD pilot study

AU - Veenis, Jesse F.

AU - Radhoe, Sumant P.

AU - Van Mieghem, Nicolas M.

AU - Manintveld, Olivier C.

AU - Caliskan, Kadir

AU - Birim, Ozcan

AU - Bekkers, Jos A.

AU - Boersma, Eric

AU - Lenzen, Mattie J.

AU - Zijlstra, Felix

AU - Brugts, Jasper J.

N1 - Funding Information: This work was supported by Abbott with an independent research grant, partially covering personnel costs. This study was investigator-initiated and was designed, conducted, interpreted and reported independently of the funder by the CRO/sponsor Erasmus University Medical Center. JJ Brugts has received speaker fees from Abbott. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2021

PY - 2021/8

Y1 - 2021/8

N2 - Aim: We aimed to assess the safety and feasibility of using CardioMEMS monitoring in patients before and after left ventricular assist device (LVAD) surgery. Patients and methods: Ten patients accepted for elective LVAD surgery were included, received a CardioMEMS at baseline and were categorized based on mean pulmonary artery pressure (mPAP) ?25 mmHg (n = 4) or mPAP >25 mmHg [n = 6]) before LVAD surgery. Results: The combined end point of all-cause mortality, acute kidney injury and/or renal replacement therapy, and right ventricular failure occurred more often in patients with an mPAP >25 mmHg (83 vs 0%, p = 0.017). Conclusion: This pilot study demonstrates that combining CardioMEMS monitoring with LVAD therapy is safe and generates the hypothesis that patients with an mPAP >25 mmHg before LVAD surgery identify a very high-risk group for adverse clinical outcomes.

AB - Aim: We aimed to assess the safety and feasibility of using CardioMEMS monitoring in patients before and after left ventricular assist device (LVAD) surgery. Patients and methods: Ten patients accepted for elective LVAD surgery were included, received a CardioMEMS at baseline and were categorized based on mean pulmonary artery pressure (mPAP) ?25 mmHg (n = 4) or mPAP >25 mmHg [n = 6]) before LVAD surgery. Results: The combined end point of all-cause mortality, acute kidney injury and/or renal replacement therapy, and right ventricular failure occurred more often in patients with an mPAP >25 mmHg (83 vs 0%, p = 0.017). Conclusion: This pilot study demonstrates that combining CardioMEMS monitoring with LVAD therapy is safe and generates the hypothesis that patients with an mPAP >25 mmHg before LVAD surgery identify a very high-risk group for adverse clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85116033901&partnerID=8YFLogxK

U2 - 10.2217/fca-2020-0182

DO - 10.2217/fca-2020-0182

M3 - Article

C2 - 33410726

AN - SCOPUS:85116033901

SN - 1479-6678

VL - 17

SP - 885

EP - 898

JO - Future Cardiology

JF - Future Cardiology

IS - 5

ER -

Remote hemodynamic guidance before and after left ventricular assist device implantation: Short-Term results from the HEMO-VAD pilot study

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this